OR WAIT null SECS
Observations from recent digital health events and a glimpse of what’s ahead—from Milan to Boca Raton
Fall was a busy conference season for digital health experts across the globe. Over the past four months, we’ve been fortunate to attend events large and small, including DTx East in Boston, MA, Frontiers Health in Milan, Italy, DTx Asia in Seoul, South Korea, HLTH in Las Vegas, NV, and wrapping up with CNS Summit in Boca Raton, FL. All were impacted by logistical challenges and last-minute dropouts of panelists due to the seasonal increase in COVID-19, influenza, and RSV cases across the globe. Yet for those who were able to attend, they were insightful. Each event sparked new ideas and concepts as we close out 2022, and look ahead to 2023 and beyond.
Most notable was the explosion in activity and the elevated profile of digital health. Digital health had a massive profile at HLTH, Frontiers Health, and CNS Summit, with digital health executives sitting on various panels to discuss the contributions of digital tools to behavioral health, drug efficacy, drug development, and virtual care. They also spoke to challenges in reimbursement and scalability, health equity and accessibility, patient engagement, and technology overload for providers. DTx East was the largest digital therapeutics-focused conference to date with over 400 in-person attendees, representing both an increasing level of activity in the DTx space and an increasing breadth of DTx-adjacent solutions including digital patient monitoring and digital prognostic apps. DTx Asia was the first-ever international conference to be held on digital therapeutics, symbolic of the rapid growth of digital health across the Asia Pacific region.
So, what’s on the horizon for 2023? Here are a few observations.
The year 2023 is shaping up to be an exciting time to be developing and launching digital medicine products that could transform the way care is delivered on a global level. Many lessons have been learned from the recent past, and attitudes from providers, payers, regulators and large pharma are moving in the right direction globally as evidenced by recent actions by all stakeholders. We can’t wait to see how quickly progress continues across the industry.
About the Authors
Scott Snyder, PhD (left), is Chief Digital Officer, and Martin Culjat, PhD (right), is the Senior Vice President and Global Head of Digital Medicines & Regulatory Innovation, both at EVERSANA.